$40,047,000,000,000 ÷ 342,800,000 Americans = $116,686 each. That's your cut of the bill. Newborns included. The debt was $19.95T the day Trump was first sworn in. It has more than doubled since. $3.83 trillion added in this term alone. CBO thought we'd hit $40T in 2028. We beat the projection by two years. And we got here faster partly because the tariff revenue he promised would pay for everything got invalidated and refunded. Customs receipts have run negative three months straight. Meanwhile the "One Big Beautiful Bill" is scored at +$3.4T through 2032. Interest alone now tops $1 trillion a year — the government's second-biggest expense, behind only Social Security. DOGE was going to fix this. How's that going?

Yesterday, @USAttyPirro announced that Secession Golf Club, Inc. agreed to pay $1,047,991 to resolve allegations that the club violated the False Claims Act when it applied for and received a loan under the Paycheck Protection Program (“PPP”) for which it was not eligible.

BREAKING: SpaceX officially completes its $60 billion acquisition of Cursor. The merger became effective on August 14, 2026. SpaceX subsidiary X67 Inc. merged into Anysphere, with Cursor surviving as a wholly owned SpaceX subsidiary. • Cursor’s common and preferred shares were converted into the right to receive 389,289,254 SpaceX Class A shares. • Vested Cursor RSUs were converted into the right to receive 1,752,426 SpaceX Class A shares before applicable tax withholding. • Cash will be provided in place of fractional shares. • Unvested Cursor RSUs were assumed and converted into approximately 29,128,326 SpaceX RSUs. • Cursor stock options were assumed and converted into approximately 44,365,047 options to purchase SpaceX Class A shares. • The share conversion was based on Cursor’s $60 billion implied equity value and SpaceX’s volume-weighted average closing price over the seven trading days immediately before closing. • The shares were issued under the Section 4(a)(2) registration exemption as a transaction that did not involve a public offering.

Crypto update: #Bitcoin# 63022.00 -0.12% #Ether# 1878.50 -0.11% #BitcoinCash# 202.72 -0.51% #EOS# 0.1295 +0% #Litecoin# 44.16 +0% #Stellar# 0.1565 -0.82% #Dogecoin# 0.0695 -0.43% #Uniswap# 3.2273 -0.47% #Chainlink# 9.3592 -2.1% #Polkadot# 0.7570 -1.16% #Solana# 75.2800 -0.32% #Avalanche# 6.3200 -2.62% #NEO# 1.686 +0%

DOW JONES UNOFFICIALLY CLOSES DOWN 8.24 POINTS, OR 0.02 PERCENT, AT 53,561.20 S&P 500 UNOFFICIALLY CLOSES DOWN 17.39 POINTS, OR 0.22 PERCENT, AT 7,713.60 NASDAQ UNOFFICIALLY CLOSES DOWN 124.63 POINTS, OR 0.47 PERCENT, AT 26,416.72

This guy missed out on over $2M in profit on $PONS! He spent just 0.25 $ETH ($610) to buy 19.98M $PONS, then sold it for 0.47 $ETH ($1,166), making only $556 in profit. Those 19.98M $PONS are now worth $2.2M — he missed out on over $2M in profit.

🚨 This may be the most consequential oncology study of 2026. Yes, on par with daraxonrasib. At #ASCO26# we highlighted the 5-year KEYNOTE-942 data for the individualized mRNA cancer vaccine intismeran + pembrolizumab in resected high-risk melanoma. And the numbers were 👀 RFS HR 0.51 5-year RFS: 68.8% vs 49.1% DMFS HR 0.41 OS HR 0.47 (still immature) Amazing data. But 157 patients. Phase IIb. The big question: does it hold up in phase III? Apparently, yes. 🔥 INTerpath-001 randomized 1,137 patients with resected stage IIB-IV melanoma to intismeran + pembrolizumab vs pembrolizumab alone. At the prespecified interim analysis: ✅ RFS met ✅ DMFS met ✅ Statistically significant AND ✅ No new safety signals We don’t have the HRs yet. So some restraint until we see the actual data (also this is a press release, so grain of salt) But why is this such a big deal? Because this isn’t really about melanoma. 🧬 Sequence YOUR tumor 🎯 Identify YOUR neoantigens 💉 Manufacture a vaccine specifically for YOUR cancer 🦠 Train YOUR immune system to recognize it And now that approach has succeeded in a randomized phase III trial. This is actually personalized. And if this platform works across tumor types, the implications are enormous. Daraxonrasib may change how we treat RAS-driven cancers. INTerpath-001 may change how we think about cancer vaccines altogether. 2026 has been an amazing year for oncology advances. 🔥 @OncoAlert @Onco_Nexus @TheGutOncLab